Pay in 4 interest-free payments of $6.12 Learn more
Ships within 48 hours · Estimated delivery Oct 3 - Oct 8
As the field evolves, its crucial for healthcare leaders and organizations to stay agile, adapt to new trends, and focus on what matters most for patients and providers, namely: GLP1s are now firstline therapies: Adoption has accelerated from just 3% in 2021 to more than 23% in 2025, displacing longstanding generics like metformin
Peptides 2023;162:170955.ArticlePubMed 109
GLP-1 usually only increases insulin production when blood glucose levels are high [11]
Moreover, the combined treatment of sDPP4 and LPS leads to increased expression and secretion of the pro-inflammatory cytokines, TNF and IL-6
Epidemiological evidence from large cohort studies The strongest population-level evidence comes from a study published on medRxiv that compared allodynia incidence between GLP-1 receptor agonist users and users of bupropion-naltrexone, an alternative weight management medication
A rare hormonal disorder, acromegaly is often caused by a tumor in the pituitary gland
